Dynavax Receives $600,000 SBIR Grant for TLR Research

BERKELEY, CA, Sep 07, 2011 (MARKETWIRE via COMTEX) -- Dynavax Technologies Corporation /quotes/zigman/84994/quotes/nls/dvax DVAX +1.75% today announced the receipt of a two-year Small Business Innovation Research grant (SBIR) for $600,000. The Award is provided by the National Institute of Allergy and Infectious Diseases and will be used to fund research to characterize the role of the phosphoinositide 3-kinase (PI3K) in preclinical models of skin autoimmune inflammation.

Scientists at Dynavax have shown that PI3K is required for the production of type I interferon (IFN) by plasmacytoid dendritic cells (PDC) in response to TLR7 or TLR9 stimulation (Journal of Experimental Medicine 2008). In subsequent studies, the chronic activation of PDC and the IFN that they produced was shown to play a role in skin autoimmune inflammation (Journal of Experimental Medicine 2010), which makes PI3k an attractive target for skin diseases such as psoriasis, cutaneous lupus, and dermatomyositis.

"This new grant supports preclinical studies focused on this key component of the TLR signaling pathway as a target for the treatment of inflammatory skin disorders. This work could well be complementary to our GSK development partnership focused on TLR inhibitors," commented Robert L. Coffman, Ph.D., Vice President and Chief Scientific Officer of Dynavax.

About Dynavax

Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases. The Company's lead product candidate is HEPLISAV(TM), a Phase 3 investigational adult hepatitis B vaccine designed to provide rapid and superior protection with fewer doses than current licensed vaccines. For more information visit www.dynavax.com .

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.